iLink™ Cross-Linking

KKeratoconuseratoconus, often referred to as “KC,” is a non-inflammatory eye condition in which the typically round dome-shaped cornea progressively thins and weakens, causing the development of a cone-like bulge and optical irregularity of the cornea. This causes “static” in your vision and can result in significant visual impairment.

Keratoconus typically first appears in individuals who are in their late teens or early twenties, and may progress for 10-20 years and then slow or stabilize. Each eye may be affected differently. In the early stages of keratoconus, people might experience:

  • Slight blurring of vision
  • Distortion of vision
  • Increased sensitivity to light

What is iLink™ FDA-Approved Cross-Linking
iLink™ corneal cross-linking is a minimally invasive outpatient procedure that combines the use of ultraviolet light and specially formulated eye drops to stiffen and strengthen corneas that have been weakened by disease or refractive surgery. Cross-linking is considered the standard of care around the world for progressive keratoconus and corneal ectasia following refractive surgery.2

Corneal Cross-Linking3

  • Creates new corneal collagen cross-links
  • Results in a shortening and thickening of the collagen fibrils
  • Leads to the stiffening of the cornea
Watch Dr. Matthew Clary and Dr. Ryan N. Mercer discuss corneal crosslinking.


Riboflavin
Under the conditions used for iLink™ corneal cross-linking, specially formulated pharmaceutical-strength riboflavin eye drops called Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) help enable the cross-linking reaction.

Ultraviolet Light (UV)
iLink™ corneal cross-linking applies an artificial source of ultraviolet light from a machine called the KXL System once the cornea has been soaked in the Photrexa® and Photrexa® Viscous eye drops. This process works to stiffen the cornea by increasing the number of molecular bonds, or cross-links, in the collagen.

Combining Riboflavin and UV Light
Using Photrexa® and Photrexa® Viscous riboflavin eye drops, combined with ultraviolet light from the KXL system, the iLink™ procedure stiffens and strengthens the cornea to slow or halt progressive keratoconus.

Is Cross-Linking Right for Me?
Patients who have been diagnosed with progressive keratoconus or corneal ectasia following refractive surgery should ask their doctor about iLink™ corneal cross-linking.

Our practice is proud to offer patients the first and only FDA-approved therapeutic solution for the treatment of progressive keratoconus. Now, patients who once had little to no therapeutic option to treat keratoconus have the opportunity to slow or halt the progression of this sight-threatening disease.

For more information about the iLink™ procedure for the treatment of keratoconus and corneal ectasia following refractive surgery, visit livingwithkeratoconus.com.

Contact us for more information about our life-changing services. To schedule an appointment, you may call 8​03-256-0641.

References:1. National Keratoconus Foundation. 2. Gomes JAP, Tan D, Rapuano CJ, et al. Global consensus on keratoconus and ectatic diseases. Cornea. 2015;34(4):359-369. 3. Beshwati IM, O’Donnell C, Radhakrishnan H. Biomechanical properties of corneal tissue after ultraviolet-A-riboflavin crosslinking. J Cataract Refract Surg. 2013;39(3):451-462.

 Spotlight

TECNIS® Symfony IOL
The first and only presbyopia-correcting extended range of vision IOL.
TECNIS® Symfony IOL
button_learnmore

Glaucoma & iStent
iStent works to help control your eye pressure by improving the outflow of fluid from your eyes.
iStent
button_learnmore

Diabetic Eye Disease
Diabetic eye disease is the leading cause of blindness in the 20-64 year age group.
Diabetic Retinopathy
button_learnmore

LenSx® Femtosecond Laser
The LenSx® Laser is the first femtosecond laser cleared by the FDA for use in cataract surgery.
LenSx® Femtosecond Laser
button_learnmore